Skip to Main Content
Diseases of the Digestive System - Liver | Hepatitis, Phase Pilot

Digoxin In Alcohol Associated Hepatitis

What is the purpose of this trial?

Acute alcohol associated hepatitis (also known as AlcHep) is an illness that results from alcohol consumption. Patients with the severe form of AlcHep have up to 40% mortality within 6 months after diagnosis. There are no approved drugs to treat AlcHep. Pre-clinical studies show that digoxin, a drug currently used in the treatment of heart failure and other heart conditions, can improve liver injury associated with alcohol use. The main goal of this study is to assess the feasibility of conducting a future large clinical trial with respect to patient recruitment, digoxin administration and dose adjustment in patients admitted to the hospital with severe AlcHep.

  • Trial with
    Yale University School of Medicine
  • Ages
    21 years - 65 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Banini Research

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    04/14/2024
  • Study HIC
    #2000030659